Vaccines: News and Research on COVID-19 Vaccines

MeSH tree: D20.215.894.899.085

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialized in mRNA technology with the goal of advancing cancer treatments.

page 2 from 16